Here are some interesting Myeloma journal articles and some of the most discussed on Twitter for September 2021.
Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to whites: a propensity-score matched analysis
Journal Of Hematology
Patel R et. al
Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy.
Journal Of Cancer
Yanjuan HeFangping Chen
Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
Cell Death & Disease
Sara PetilloMarco Cippitelli
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: a randomised phase 2 trial by the Nordic Myeloma Study Group.
European Journal Of Haematology
Henrik GregersenNina Gulbrandsen
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
Cell Death & Disease
Tian XiaPeipei Xu
S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma.
Frontiers In Cell And Developmental Biology
Minxia LiuCaroline A Heckman
Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma.
Chinese Medical Journal
Tian-Tao GaoJin Xiang
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Blood Cancer Journal<, em>
Karthik Ramasamy, Hearn Jay Cho
Acute Kidney Injury in Monoclonal Gammopathies.
Journal Of Clinical Medicine
Paolo MenèFrancescaromana Festuccia
Strategies to Overcome High-Risk Multiple Myeloma.
The Cancer Journal
Larysa Sanchez